MDNA News and Press, Medicenna Therapeutics Corp. From 11/12/21

Medicenna Therapeutics has engineered super-versions of interleukins, proteins that mediate communication between cells. Medicenna’s candidate for treating rGBM, MDNA55, has shown promising efficacy and safety data in its recently concluded phase II trial. MDNA11, an IL-2 s...

Medicenna Therapeutics Corp. (MDNA) Q2 2022 Results Earnings Conference Call November 12, 2021, 08:30 AM ET Company Participants Dan Ferry - Managing Director-LifeSci Advisors Fahar Merchant - President & Chief Executive Officer Mann Muhsin - Chief Medical Officer Rosemina Merchant - Chie...

Medicenna Therapeutics (NASDAQ:MDNA): FQ2 GAAP EPS of -C$0.15. Medicenna had cash, cash equivalents, and marketable securities of C$26.7 million at September 30, 2021. These funds provide the Company with sufficient capital to execute its current planned expenditures through the end of calend...

-- Phase 1/2 ABILITY Study of MDNA11 on track for preliminary data updates in calendar 2021 and mid-calendar 2022 -- Management hosting conference call and webcast today at 8:30 am ET TORONTO and HOUSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (...

TORONTO and HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the...

TORONTO and HOUSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on November 12, 2021 at 8:30 AM ...

Guardion Health Sciences (NASDAQ:GHSI) +53%. RISE Education Cayman (NASDAQ:REDU) +20% on receipt of prelim non-bidding proposal to acquire all company assets Kaival Brands Innovations (NASDAQ:KAVL) +25% FDA enters administrative stay of Bidi Vapor's marketing denial order for i...

-- ABILITY Study is currently ongoing at clinical trial sites in Australia -- Preliminary update on safety, PK/PD, and biomarker data expected by year-end 2021 -- Initial efficacy data update expected in mid-2022 TORONTO and HOUSTON, Oct. 27, 2021 (GLOBE NEWSWIRE) ...

-- MDNA11 preferentially induced durable proliferation and expansion of anti-cancer immune cells with limited stimulation of pro-tumor Treg cells in non-human primates (NHP) -- MDNA11 administration in NHPs did not lead to safety issues typically associated with IL-2 -- ...

The following slide deck was published by Medicenna Therapeutics Corp. in conjunction with this event. For further details see: Medicenna Therapeutics (MDNA) Next-Gen Cytokine Therapeutics Summit Presentation - Slideshow